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Islet amyloidosis is characterized by the aberrant accumulation of islet amyloid polypeptide
(IAPP) in pancreatic islets, resulting in b cell toxicity, which exacerbates type 2 diabetes and
islet transplant failure. It is not fully clear how IAPP induces cellular stress or how IAPP-
induced toxicity can be prevented or treated. We recently defined the properties of toxic
IAPP species. Here, we have identified a receptor-mediated mechanism of islet
amyloidosis–induced proteotoxicity. In human diabetic pancreas and in cellular and mouse
models of islet amyloidosis, increased expression of the receptor for advanced glycation
endproducts (RAGE) correlated with human IAPP–induced (h-IAPP–induced) b cell and
islet inflammation, toxicity, and apoptosis. RAGE selectively bound toxic intermediates, but
not nontoxic forms of h-IAPP, including amyloid fibrils. The isolated extracellular ligand–
binding domains of soluble RAGE (sRAGE) blocked both h-IAPP toxicity and amyloid
formation. Inhibition of the interaction between h-IAPP and RAGE by sRAGE, RAGE-
blocking antibodies, or genetic RAGE deletion protected pancreatic islets, b cells, and
smooth muscle cells from h-IAPP–induced inflammation and metabolic dysfunction.
sRAGE-treated h-IAPP Tg mice were protected from amyloid deposition, loss of b cell area,
b cell inflammation, stress, apoptosis, and glucose intolerance. These findings establish
RAGE as a mediator of IAPP-induced toxicity and suggest that targeting the IAPP/RAGE
axis is a potential strategy to mitigate this source of b cell dysfunction in metabolic disease.
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Introduction
The misfolding and aggregation of soluble proteins into amy-
loid fibrils plays a key role in a range of human diseases (1–8). 
Pancreatic islet amyloidosis is a source of β cell proteotoxic-
ity and apoptosis in type 2 diabetes (T2D) (9, 10). There are no 
treatments to prevent this disorder or to preserve β cell mass 
and function (11, 12). Pathological aggregation of the endocrine 
hormone human islet amyloid polypeptide (h-IAPP, also known 
as amylin) is a key feature in islet amyloidosis. h-IAPP is cose-
creted with insulin and plays an adaptive role in metabolism 
(6, 13–16), but in T2D, it aggregates by an unknown mechanism 
and is deposited as pancreatic islet amyloid plaques associated 
with reduced β cell volume (2, 4, 7, 8, 17, 18). Aggregation of 
h-IAPP into amyloid fibrils involves 3 observable stages: Pre-
amyloid oligomers (or prefibrillar intermediates) formed in the 
lag phase (LP) (first phase) assemble into amyloid fibrils in the 
growth phase (GP) (second phase), leading to an equilibrium 
between amyloid fibrils and residual soluble peptide in the satu-
ration phase (SP) (third phase) (Supplemental Figure 1, A and B; 
supplemental material available online with this article; https://
doi.org/10.1172/JCI85210DS1). Toxic h-IAPP aggregates cause 
pancreatic β cell and islet dysfunction and death, contributing to 
T2D, islet transplant failure, and, ultimately, cardiovascular and 
microvascular complications (19–23).
Substantial evidence reveals that both extracellular and intra-
cellular h-IAPP oligomers contribute to islet β cell toxicity. Post-
mortem histological studies of human subjects with T2D show pre-
dominantly extracellular pancreatic islet amyloid deposition (4, 6, 
17). Rodents do not develop islet amyloidosis, as rodent IAPP is non-
amyloidogenic and nontoxic (17, 24, 25), but a variety of Tg h-IAPP 
rodent models have been created that form either extracellular 
or intracellular islet amyloid, or both (26). Mice that overexpress 
h-IAPP demonstrate intracellular oligomer formation and defects 
in autophagy and/or ER stress (27–30), while cultured Tg murine 
islets expressing physiological levels of h-IAPP do not display ER 
stress during islet amyloidosis (31). Extracellular h-IAPP oligomers 
are toxic (6, 19, 32–35). Findings that h-IAPP secretion is necessary 
for β cell proteotoxicity and amyloid formation (32), studies that 
show extracellular h-IAPP oligomers can be translocated into β cells 
(36), and receptor-mediated mechanisms of cytotoxicity (33) all 
support a role for extracellular oligomers in h-IAPP–induced β cell 
and islet pathogenesis. Here, we focus on islet amyloidosis–induced 
proteotoxicity by extracellular h-IAPP oligomers.
Amyloidogenic h-IAPP induces β cell apoptosis in vitro, in 
rodent models in vivo, and in human T2D (10, 19, 26, 34, 35, 37, 38). 
Multiple mechanisms of toxicity have been proposed, but there is 
no consensus about how h-IAPP causes β cell damage (6, 17, 39). 
Local islet inflammation and the production of cytokines and che-
mokines have been suggested to contribute to toxicity, as have the 
disruption of cell membranes by h-IAPP aggregates; impairment 
of the ER-associated protein degradation/ubiquitin/proteasome 
(ERAD/ubiquitin/proteasome) pathway and ER stress; defects in 
autophagy; activation of NADPH-oxidase and consequent oxida-
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highly effective therapeutic agent to prevent both h-IAPP toxicity 
and amyloid formation in vivo. These findings highlight RAGE as 
a therapeutic target for β cell preservation in metabolic disease 
and provide critical information for the design of inhibitors of 
h-IAPP/RAGE interactions.
Results
RAGE is upregulated in h-IAPP–induced β cell and islet proteotoxic-
ity. We have shown that toxic h-IAPP LP intermediates, but not 
nontoxic h-IAPP amyloid fibrils, induce the production of ROS in 
INS-1 β cells and that this event precedes the detection of meta-
bolic dysfunction (19). If RAGE is a mediator of h-IAPP–induced β 
cell toxicity, then we would expect that toxic h-IAPP LP interme-
diates would likewise upregulate RAGE expression before detect-
able loss of β cell viability. This was indeed the case. We prepared 
solutions of h-IAPP LP intermediates, determined that they were 
prefibrillar by the amyloid-sensitive dye thioflavin-T and by trans-
mission electron microscopy (TEM) (Figure 1, A and B), and incu-
bated them with rat INS-1 β cells for a short period of time (1 hour), 
which does not provoke loss of cell viability (Supplemental Figure 
3A) (19), as well as a longer incubation time (5 hour), which is 
required to detect metabolic dysfunction in cellular toxicity assays 
(Figure 1C). The results demonstrated that exogenous h-IAPP LP 
intermediates upregulated β cell RAGE protein expression within 
1 hour of peptide incubation on cells, preceding the detection of β 
cell dysfunction (Supplemental Figure 3, A and B). We observed 
similar results during high-glucose–induced β cell stress. INS-1 β 
tive stress; and receptor-mediated mechanisms linked to the acti-
vation of signaling cascades and cleavage of caspases leading to 
apoptosis (19, 27–30, 33–35, 38, 40–46). The available data suggest 
that h-IAPP exerts its toxic effects on β cells by multiple overlap-
ping mechanisms that share common signaling pathways, several 
of which have yet to be characterized (39). We recently defined the 
molecular properties of toxic h-IAPP intermediates using time-
resolved studies coupling biophysical and biological methods. 
These studies enable us to investigate proteotoxicity under well-
defined conditions (19).
We hypothesized that the receptor for advanced glyca-
tion endproducts (RAGE) contributes to h-IAPP–induced islet 
β cell toxicity, as RAGE activates mediators of oxidative stress, 
inflammation, and apoptosis that are known to be upregulated in 
h-IAPP–induced cytotoxicity (47). RAGE, a pattern recognition 
receptor involved in a diverse range of inflammatory diseases 
including diabetes, engages multiple families of ligands with 
different properties. The accumulation and binding of ligands 
upregulate RAGE expression and transduce intracellular signal-
ing, leading to β cell and islet stress and apoptosis (48–50). It is not 
known whether RAGE plays a role in islet amyloidosis–induced β 
cell proteotoxicity. Here, we demonstrate that toxic preamyloid 
h-IAPP intermediates, but not amyloid fibrils or nontoxic forms 
of IAPP, bind to RAGE and upregulate β cell RAGE expression and 
that blockade of RAGE inhibits h-IAPP–induced β cell and islet 
inflammation, apoptosis, and glucose intolerance in pancreatic 
islet amyloidosis. We establish that soluble RAGE (sRAGE) is a 
Figure 1. Toxic, preamyloid h-IAPP intermediates upregulate RAGE expression in β cells. h-IAPP LP species, SP amyloid fibrils, and r-IAPP aggregates 
were characterized by (A) thioflavin-T binding, (B) TEM (scale bars: 100 nm), and (C) Alamar Blue metabolic assays. (D) WB studies measuring RAGE 
protein. In C and D, β cells were treated with peptide solutions for 5 hours. RAGE levels in D were normalized to GAPDH levels and presented as the fold-
change relative to r-IAPP–treated β cells. The final peptide concentration in cellular assays was 14 μM. In D, data were taken from 2 distinct WBs in order 
to accommodate all of the conditions; in both cases, comparisons were made with h-IAPP (LP) species. Data represent the mean ± SD (thioflavin-T and 
metabolic assays) and the mean ± SEM (WBs) of 3 to 4 independent experiments (3–6 technical replicates per experiment). The graphs in A–C represent 
more than 20 experiments repeated at different times using multiple different preparations of primary peptide stock solutions. NSD, no statistical differ-
ence. *P < 0.05, **P ≤ 0.01, and ****P ≤ 0.0001, by 1-way ANOVA.
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WT murine pancreatic islets, which 
showed significant upregulation of 
RAGE protein expression after treat-
ment with toxic h-IAPP LP intermedi-
ates compared with nontoxic r-IAPP 
(Supplemental Figure 5). These 
results provide clear evidence that 
toxic h-IAPP LP intermediates, and 
not other forms of h-IAPP including 
amyloid fibrils, upregulate RAGE pro-
tein levels in β cells and primary islet 
cells and demonstrate that this initial 
event precedes β cell dysfunction.
RAGE binds specifically to the 
toxic form of h-IAPP, but not to its 
nontoxic forms. RAGE is ubiquitously 
expressed on the surface of cells at low 
levels in homeostasis, and circulating 
h-IAPP plays an adaptive role in met-
abolic regulation. Thus, we expected 
that RAGE would not bind to the non-
toxic functional form of h-IAPP. If 
RAGE plays a role in islet amyloidosis 
toxicity, we would also expect that its 
soluble extracellular ligand–binding 
domains (sRAGE) would bind to 
toxic h-IAPP intermediates, but not 
to nontoxic amyloid fibrils. This is 
exactly what we observed. We tested 
the ability of different h-IAPP species 
that form during amyloid formation 
to bind sRAGE. In these experiments, 
h-IAPP amyloid formation was initi-
ated (25°C) by dissolving lyophilized 
peptide with buffer (time zero, t0). 
sRAGE was added at a 1:1 molar ratio 
to aliquots of the h-IAPP solution at 
different time points during amyloid 
formation (Supplemental Figure 1B 
and Supplemental Figure 2A), and 
binding studies were performed 
concurrently with cellular metabolic 
assays and TEM.
The hydrophobic patch of sRAGE 
contains 3 tryptophan (Trp, also 
known as W) residues, 2 of which, 
W61 and W72, are partially solvent exposed (Supplemental Figure 
2). Ligand binding to this region changes the fluorescent quantum 
yield of these Trp residues. Neither h-IAPP nor r-IAPP contain any 
Trp residues. Thus, quenching of sRAGE Trp fluorescence in the 
presence of IAPP peptides affords an independent probe to monitor 
IAPP/sRAGE binding (Supplemental Figure 1A and Supplemental 
Figure 2). Simultaneous Trp fluorescence and thioflavin-T bind-
ing studies showed a time-dependent wave of sRAGE Trp fluores-
cence quenching, with time points of maximum fluorescence loss 
(denoted by § in Figure 2, B–D) occurring within the LP, indicating 
that prefibrillar h-IAPP intermediates bound RAGE (Figure 2, B and 
cells incubated at a high glucose concentration (16.7 mM) showed 
an increase in RAGE protein levels compared with cells cultured at 
a standard glucose concentration (11.7 mM), which also preceded 
detectable glucotoxicity (Supplemental Figure 4, A and B). These 
results are consistent with a role for RAGE in β cell stress.
In contrast to the 1 hour incubation period, a longer 5 hour 
incubation resulted in significant cellular toxicity along with 
elevated RAGE protein levels (Figure 1, C and D). Treatment of 
β cells with either nontoxic rat IAPP (r-IAPP) or nontoxic h-IAPP 
amyloid fibrils did not increase RAGE expression (Figure 1, C and 
D). These findings were recapitulated in studies with isolated 
Figure 2. RAGE binds only to the toxic, prefibrillar form of h-IAPP. (A) Schematic diagram showing the 
design of h-IAPP/sRAGE binding experiments. Blue arrows indicate the time points at which sRAGE was 
added to h-IAPP over the course of amyloid formation. (B) In the sRAGE Trp fluorescence assays, a 1:1 molar 
addition of sRAGE to h-IAPP (blue circles) led to a wave of fluorescence quenching that mirrored the wave 
of h-IAPP toxicity shown in D. No change in fluorescence was observed for sRAGE alone (black squares) or 
with a 1:1 molar addition of sRAGE to r-IAPP (white triangles). h-IAPP, in the absence of sRAGE (red circles), 
and r-IAPP, in the absence of sRAGE (green triangles), were used as nonfluorescent controls. (C) Thioflavin-
T–binding assays, carried out concurrently with sRAGE Trp fluorescence assays and β cell metabolic assays, 
monitored the kinetics of amyloid formation (25°C) in the peptide solutions used in the experiments shown 
in B and D. h-IAPP (red circles) and r-IAPP (green triangles). (D) Time-resolved Alamar Blue metabolic assays 
in INS-1 β cells treated with h-IAPP (red circles) or r-IAPP (green triangles) demonstrated that LP intermedi-
ates were the most toxic form of h-IAPP. (E) SPR shows that sRAGE bound h-IAPP LP intermediates (blue 
line) but not t0 species (black dashed line) or SP amyloid fibrils (red dashed line). In B–D, the symbol (§) 
indicates the time point at which the maximum sRAGE Trp fluorescence quenching was observed. The final 
peptide concentration after transferring peptide aliquots into β cell assays was 14 μM. Data are representa-
tive of 3 to 10 independent experiments. Data in C and D represent the mean ± SD of a minimum of 3 to 6 
technical replicates per time point. Error bars for some data points are smaller than the size of the symbols.
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tion, since it selectively binds toxic LP intermediates. We add-
ed sRAGE to h-IAPP at different time points over the course of 
aggregation (Figure 2A) and monitored the effect on the kinetics 
of amyloid formation using thioflavin-T binding assays, differ-
ence circular dichroism (CD), and TEM (Figure 3). Thioflavin-T 
assays indicate which h-IAPP species sRAGE targets; CD probes 
the development of secondary structure; and TEM confirms the 
presence or absence of amyloid. Specifically, we prepared 1 pri-
mary stock solution of sRAGE and 1 primary stock solution of 
h-IAPP, from which aliquots were removed and mixed at various 
time points during amyloid formation to produce 5 different sam-
ples of h-IAPP/sRAGE mixtures: (a) h-IAPP/sRAGE t0 species; (b) 
h-IAPP/sRAGE early LP (ELP) species; (c) h-IAPP/sRAGE mid-
LP (MLP) species; (d) h-IAPP/sRAGE GP species; and (e) h-IAPP/
sRAGE amyloid fibrils in the SP. The kinetics of amyloid forma-
C). We observed no quenching at t0. sRAGE fluorescence quench-
ing diminished during the GP and was not detectable in the SP. The 
time course for sRAGE Trp fluorescence quenching mirrored the 
time course for h-IAPP toxicity, confirming that the RAGE-binding 
h-IAPP intermediates were toxic to β cells (19) (Figure 2, B–D). 
sRAGE did not bind nontoxic r-IAPP at any time point in these stud-
ies (Figure 2B). Surface plasmon resonance (SPR) experiments, cou-
pled with TEM studies, confirmed these results. SPR data showed 
that sRAGE bound to transient preamyloid LP species, but not to t0 
species or amyloid fibrils (Figure 2E). TEM experiments verified the 
absence of amyloid fibrils in samples that bound sRAGE (Supple-
mental Figure 6, A–C). The results of these experiments demon-
strate that toxic h-IAPP intermediates are ligands of RAGE.
sRAGE is an inhibitor of amyloid formation by h-IAPP. We 
hypothesized that sRAGE would inhibit h-IAPP amyloid forma-
Figure 3. sRAGE targets prefibrillar h-IAPP LP intermediates and inhibits amyloid formation. (A) Thioflavin-T–monitored kinetics of h-IAPP amyloid 
formation after the addition of sRAGE at different time points (15°C). Arrows indicate the time points at which sRAGE was added to different kinetic spe-
cies of h-IAPP: prefibrillar ELP species (orange), prefibrillar MLP species (green), fibrillar GP species (purple), and SP amyloid fibrils (blue). h-IAPP without 
sRAGE (red) was used as a positive control for amyloid formation. (B) Difference-CD studies showed the effect of sRAGE on h-IAPP secondary structure 
formation: t0 species (black), ELP species (orange), MLP species (green), LLP species (purple), and SP amyloid fibrils (blue). CD spectra of samples were 
recorded after a 48-hour incubation. h-IAPP readily formed amyloid by itself in the absence of sRAGE (red), but sRAGE inhibited β-sheet formation when 
added to h-IAPP at time points before the formation of toxic LP intermediates or when they were present, demonstrating that inhibition by sRAGE was 
sustained and not transient. The inhibitory effects of sRAGE on h-IAPP β-sheet formation decreased as it was added to h-IAPP at later time points in the 
LP. (C–H) Representative TEM images show the morphology of protein species at time points assessed by difference-CD. (C) Amorphous sRAGE alone, (D) 
h-IAPP SP amyloid fibrils, and the effect of the addition of sRAGE on different h-IAPP kinetic species: (E) ELP species, (F) MLP species, (G) LLP species, 
and (H) SP amyloid fibrils. Scale bars: 200 nm. The final peptide concentration in biophysical experiments was 20 μM. Thioflavin-T, CD, and TEM data are 
representative of 3 to 5 independent experiments. Data in A represent the mean ± SD of 3 to 6 technical replicates per time point. Error bars for some data 
points are smaller than the size of the symbols. incub, incubation.
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cies. The data indicate that addition of sRAGE to ELP or MLP spe-
cies prevented amyloid formation but that sRAGE had no effect 
when added during the GP or SP (Figure 3A). These data are sup-
ported by difference-CD and TEM studies (Figure 3, B–H). The 
data show that addition of sRAGE to h-IAPP at or before time 
points of toxic species formation prevented β-sheet formation, as 
detected by difference-CD (Figures 3B and Supplemental Figure 
7, A–F), and amyloid formation, as detected by TEM (Figure 3, 
C–F). The data also show that sRAGE had less of an effect when it 
was added later in the LP (Figure 3, B and G). Thus, sRAGE spe-
tion in each sample was then monitored by thioflavin-T binding, 
difference-CD, and TEM. Aliquots from the original h-IAPP and 
sRAGE stock solutions were measured at the same time points, 
serving as control solutions.
A decrease in temperature increases the length of the LP 
of amyloid formation, facilitating the identification of distinct 
events in the LP. Thus, we performed the sRAGE/h-IAPP binding 
experiments at lower temperatures (15°C) than those conducted 
in the absence of sRAGE depicted in Figure 2C (25°C) to better 
resolve the effect of adding sRAGE to different h-IAPP LP spe-
Figure 4. sRAGE inhibits h-IAPP–induced inflammatory gene expression in β cells. qPCR analysis of INS-1 β cells treated (5 hour) with h-IAPP LP inter-
mediates, a 1:1 molar ratio of h-IAPP/sRAGE, sRAGE alone, r-IAPP, or buffer. The final peptide concentration after transferring aliquots into β cell assays 
was 14 μM. Data represent the mean ± SEM of 3 to 4 independent experiments (3–9 technical replicates per experiment) and are presented as the fold 
change relative to buffer-treated β cells. *P < 0.05 and **** P ≤ 0.0001, by 1-way ANOVA.
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cifically targets species that reside early in the LP and blocks amy-
loid formation by sequestering them and preventing their further 
assembly into fibrils.
RAGE significantly contributes to h-IAPP–mediated cellular 
proinflammatory gene expression and cytotoxicity. Our finding that 
toxic h-IAPP LP intermediates bound RAGE and upregulated 
β cell RAGE expression led us to predict that LP intermediates 
would modulate inflammatory gene expression and cytotoxicity 
in cultured β cells and muscle cells, as h-IAPP–induced islet cell 
and cardiomyocyte inflammation have been reported (40, 42, 44, 
45, 51). We also expected that sRAGE would compete with cell- 
surface RAGE for h-IAPP binding, as it targets toxic LP intermedi-
ates and is a competitive inhibitor of ligand binding to cell mem-
brane–bound RAGE. To test this, we used INS-1 β cells and primary 
murine aortic smooth muscle cells (SMCs) as model systems (50, 
52). We prepared h-IAPP LP intermediates, a 1:1 molar mixture of 
h-IAPP/sRAGE, and multiple controls including sRAGE, r-IAPP, 
and buffer-only solutions. We then characterized each sample and 
added aliquots to cultured cells for concurrent real-time quantita-
tive PCR (qPCR) and Western blot (WB) studies.
We found that h-IAPP LP intermediates significantly upregu-
lated mRNA transcripts of Ager (the gene encoding RAGE), Ccl2, 
Cxcl1, Cxcl2, Il1b, Il18, and Tnfa, and that treatment of the β cells 
with sRAGE during h-IAPP challenge reduced proinflammatory 
gene expression. h-IAPP LP intermediates exerted no significant 
effect on the regulation of antiinflammatory Il10. sRAGE alone, 
like r-IAPP and buffer, had no independent effect on the regula-
tion of any of the examined inflammatory mediators (Figure 4).
We conducted WB experiments using INS-1 β cells in parallel 
with qPCR, thioflavin-T, and cell viability studies and observed that 
the upregulation of β cell inflammatory markers and proteotoxic-
ity by h-IAPP LP intermediates was RAGE dependent. WB data in 
Figure 5 show that preamyloid h-IAPP intermediates significantly 
increased RAGE protein expression and that blocking h-IAPP/
sRAGE interactions using sRAGE prevented h-IAPP–induced 
RAGE upregulation. We obtained similar results using RAGE-
expressing primary murine aortic SMCs (Supplemental Figure 8A).
We next tested the effect of blocking cellular h-IAPP/sRAGE-
interactions on h-IAPP–induced toxicity toward RAGE-expressing 
murine pancreatic islets, β cells, and SMCs using 3 independent 
strategies: treatment with sRAGE, treatment with RAGE-blocking 
antibodies (IgGs) that directly block cellular RAGE/ligand inter-
actions, and genetic deletion of RAGE (Ager–/–). We found that the 
addition of sRAGE protected pancreatic islet cells, INS-1 β cells, 
and SMCs from h-IAPP–induced metabolic dysfunction (Figure 
6, A and B, and Supplemental Figure 8B). Pretreatment of INS-1 β 
cells with increasing concentrations of anti–RAGE IgG (blue bars, 
Figure 6C) inhibited metabolic dysfunction by h-IAPP LP interme-
diates in a dose-dependent manner, unlike what we observed with 
control IgG (red bars, Figure 6C). Primary pancreatic islets isolated 
from Ager–/– mice (blue bars, Figure 6, D and E) showed significant 
protection from h-IAPP toxicity compared with islets from age-
matched RAGE-expressing (Ager+/+) WT mice (red bars, Figure 6, 
D and E). We obtained similar results when we added h-IAPP LP 
intermediates to cultured WT (red bars, Supplemental Figure 8C) 
versus Ager–/– (blue bars, Supplemental Figure 8C) murine aortic 
SMCs. Together, the results indicate that RAGE plays a key role in 
mediating h-IAPP toxicity to cells and pancreatic islets.
RAGE is upregulated in hemi_h-IAPP mice in concert with pro-
inflammatory gene expression and β cell stress and apoptosis, and 
treatment with sRAGE ameliorates islet amyloidosis–induced pathol-
ogy and metabolic dysfunction. To examine the role of RAGE in 
h-IAPP–induced β cell toxicity in vivo and assess the potential effi-
cacy of sRAGE as a therapeutic agent for β cell and islet preserva-
tion in islet amyloidosis, we used hemizygous Tg mice that express 
RAGE, overexpress h-IAPP (hemi_h-IAPP mice), and develop β 
cell degeneration and islet amyloidosis pathology but not diabe-
tes (26, 53). This prediabetic model decouples the role of RAGE 
in islet amyloidosis–induced β cell perturbation from the multiple 
other stress-provoking factors that exist in the complex setting of 
diabetes, including hyperglycemia-mediated formation of other 
RAGE ligands such as advanced glycation endproducts (AGEs) 
(49). The slow development of early-stage islet amyloidosis in this 
model facilitates the gradual accumulation of prefibrillar h-IAPP 
aggregates, allowing us to test the hypothesis that toxic h-IAPP 
intermediates cause RAGE-mediated β cell defects.
We treated hemi_h-IAPP and WT mice with sRAGE (100 μg/
day) or PBS 6 days a week for 10 months to inhibit in vivo h-IAPP/
RAGE interactions. Metabolic characterization confirmed defec-
tive β cell function in the hemi_h-IAPP mice at 12 months of age, 
but no diabetes, as previously reported (26, 53). The data show that 
PBS-treated hemi_h-IAPP mice (referred to hereafter as Tg/PBS 
mice) were mildly but significantly glucose intolerant compared 
with age-matched and weight-matched WT mice, but no hypergly-
cemia or significant differences in circulating insulin levels were 
Figure 5. sRAGE inhibits h-IAPP–induced upregulation of RAGE in β 
cells. Representative WB showing RAGE protein levels. WB studies were 
performed in parallel with the qPCR studies presented in Figure 4 and 
used identical conditions. RAGE levels were normalized to GAPDH levels. 
sRAGE-treated cells were washed 3 times with PBS to remove all residual 
sRAGE before harvesting. The final peptide concentration after trans-
ferring aliquots of peptide into β cell assays was 14 μM. Data represent 
the mean ± SEM of 3 to 4 independent experiments (n = 3–4 technical 
replicates per experiment) and are presented as the fold change relative to 
r-IAPP–treated cells. *P < 0.05 and **P ≤ 0.01, by 1-way ANOVA.
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observed (Figure 7, A–E). Quantitative histological analyses of pan-
creatic tissue revealed an increase in mean islet diameter in Tg/PBS 
mice compared with the WT groups (Figure 7F). Immunofluores-
cence studies of pancreas sections costained for S100B-insulin or 
AGEs-insulin confirmed the absence of these RAGE ligands in the 
β cells and islets of both treatment groups of Tg and WT mice, while 
positive control pancreas sections from diabetic high-fat diet–fed 
(HFD-fed) WT mice showed AGE and S100B immunoreactivity 
(Supplemental Figure 9 and Supplemental Figure 10). Treatment 
of hemi_h-IAPP mice with sRAGE (referred to hereafter as Tg/
sRAGE mice) protected them from islet amyloidosis–induced pre-
diabetic defects in β cell function associated with glucose intoler-
ance (Figure 7, A–E), and morphological analyses showed a signifi-
cantly lower mean islet diameter compared with that observed in 
islets from Tg/PBS mice (Figure 7F). Collectively, the results con-
firmed that hemi_h-IAPP mice develop β cell dysfunction and that 
sRAGE inhibits h-IAPP toxicity and islet pathology in vivo.
qPCR studies in whole pancreas samples revealed a similar 
induction pattern of inflammatory mediators in Tg/PBS islets in 
vivo, as was observed in the h-IAPP–treated β cells in vitro (Figure 
8). Tg/sRAGE mice were substantially protected from h-IAPP–
induced upregulation of proinflammatory gene expression, as 
indicated by significantly lower Cxcl2 and Il1b mRNA transcript 
levels compared with Tg/PBS mice and a nonsignificant trend 
toward lower Ager, Cxcl1, and Il18 gene expression. Upregula-
tion of other inflammatory processes was also observed in Tg/
sRAGE mice, as indicated by a significant increase in Il10 and 
Tnfa mRNA transcript levels (Figure 8). We observed no change 
in Ccl2 levels in Tg/sRAGE mice compared with levels in Tg/PBS 
mice. These findings confirm in vivo relevance for sRAGE as an 
inhibitor of islet amyloidosis–induced modulation of inflamma-
tory cytokines and chemokines.
Immunofluorescence studies confirm the upregulation of 
RAGE immunoreactivity in Tg/PBS islets compared with WT/PBS 
islets, as well as significant protection of Tg/sRAGE mice from 
islet amyloid deposition, β cell stress, and apoptosis. Pancreas 
sections costained for thioflavin-S and insulin indicated modest 
amyloid severity in Tg/PBS mice (Figures 9, A and B, and Supple-
mental Table 1), along with a significant decrease in the mean 
islet β cell area (from 72.4% ± 3.6% in WT/PBS mice to 59.3% ± 
2.7% in Tg/PBS mice) (Figure 9C and Supplemental Table 1). In 
contrast, we found that amyloid deposition in Tg/sRAGE mice 
Figure 6. Blocking h-IAPP/RAGE interac-
tions protects β cells and primary islets from 
h-IAPP toxicity. Alamar Blue metabolic assays 
measuring the viability of (A) rat INS-1 β cells 
and (B) primary WT murine islets after treat-
ment with solutions of h-IAPP LP intermedi-
ates, a 1:1 molar mixture of h-IAPP/sRAGE, 
r-IAPP, sRAGE alone, or buffer. (C) β cells 
pretreated (2 h) with increasing concentrations 
of either anti–RAGE IgG (blue) or IgG control 
(red) before being challenged with toxic h-IAPP 
LP intermediates. (D) Pancreatic islets isolated 
from Ager+/+ WT (red bars) or Ager–/– (blue bars) 
mice treated with h-IAPP LP species or buffer. 
(E) Light microscopic images of isolated Ager+/+ 
WT or Ager–/– murine pancreatic islets after 
hand purification. Original magnifcation ×20. 
The final peptide concentration in viability 
assays was 14 μM. Data represent the mean 
± SD of 3 to 7 independent experiments (3–6 
technical replicates per experiment). *P < 0.05, 
**P ≤ 0.01, ***P ≤ 0.001, and ****P ≤ 0.0001, 
by 1-way or 2-way ANOVA, as appropriate.
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sion in Tg/PBS versus WT/PBS islets (Figure 10, A and B, and 
Supplemental Table 1).
We observed a direct inverse relationship between islet β cell 
area and β cell stress/preapoptosis and apoptosis in Tg/PBS mice 
(Supplemental Figure 12, A and B, respectively), consistent with 
previous reports on islet amyloidosis (10). We found that loss of 
islet β cell area also directly correlated with β cell RAGE immu-
noreactivity in Tg/PBS mice (Figure 10C). These data link RAGE 
with islet amyloidosis–induced β cell toxicity and demonstrate 
that significant β cell apoptosis and a loss of β cell area do not 
require extensive islet amyloid deposition or diabetes, consistent 
with reports in other models (54). Together, the in vivo data sup-
port a role for h-IAPP-induced, RAGE-mediated β cell and islet 
defects in prediabetes and confirm that sRAGE is an effective 
pharmacological agent against islet amyloidosis–induced β cell 
stress and apoptosis.
h-IAPP upregulates β cell RAGE expression in human subjects 
with T2D and islet amyloidosis. We probed the relevance of our 
findings to human pancreas specimens bearing significant β 
cell stress using T2D and nondiabetic (ND) pancreas samples 
obtained from the Network for Pancreatic Organ Donors with 
Diabetes (nPOD). We observed thioflavin-S+ islet amyloid 
plaques in human T2D pancreas sections costained with insulin, 
was markedly reduced and that the β cell area was preserved to a 
degree comparable to that observed in WT mice (Figures 9, A–C, 
Supplemental Figure 11A, and Supplemental Table 1). These find-
ings are consistent with our in vitro data demonstrating inhibition 
of h-IAPP toxicity and amyloid formation by sRAGE.
Mild islet amyloid deposition in Tg/PBS mice was accompa-
nied by a significant increase in islet β cell stress and apoptosis 
compared with WT/PBS mice, as assessed by costaining with 
cleaved caspase-3 (CC3) and insulin and triple staining with 
TUNEL, insulin, and DAPI, respectively (Figure 9, D–G, Supple-
mental Figure 11, B and C, and Supplemental Table 1). These 
results are in line with previous studies showing increased β 
cell apoptosis in Tg mouse models overexpressing h-IAPP (26). 
Treatment of Tg mice with sRAGE led to a significant reduction 
in β cell stress and apoptosis compared with that seen in PBS-
treated Tg mice (Figure 9, D–G and Supplemental Table 1). We 
observed no statistically significant differences between sRAGE-
treated and PBS-treated WT mice, confirming that sRAGE does 
not have independent effects, delivers no harm, and offers no 
additional protection (Figures 9, E and G, Supplemental Figure 
11, B and C, and Supplemental Table 1). Pancreas sections from 
the same mice, costained for RAGE and insulin, showed a signifi-
cant increase of approximately 1.9-fold in β cell RAGE expres-
Figure 7. Physiological parameters of mice. 
The indicated mice were fed a normal chow 
diet. Treatment of mice with sRAGE (100 
μg/ml, i.p.) or PBS was started at 8 weeks 
of age and continued for 10 months prior to 
sacrifice at 12 months of age. (A) Glucose 
intolerance in Tg/PBS mice (n = 10) compared 
with Tg/sRAGE (n = 10), WT/PBS (n = 9) and 
WT/sRAGE mice (n = 5). **P < 0.01, Tg/PBS 
versus WT/PBS; ##P < 0.01, Tg/PBS versus 
Tg/sRAGE. Evaluation of (B) the area under 
ip-GTT curves up to 180 minutes; (C) body 
weights (n = 13, WT/PBS; n = 8, WT/sRAGE; 
n = 15, Tg/PBS; n = 13, Tg/sRAGE); (D) fasting 
blood glucose levels (n = 13, WT/PBS;  
n = 8, WT/sRAGE; n = 15, Tg/PBS; n = 13, Tg/
sRAGE); and (E) fasting plasma insulin levels 
(n = 10, WT/PBS; n = 8, WT/sRAGE; n = 12, 
Tg/PBS; n = 11, Tg/sRAGE) for sRAGE-treated 
(blue) and PBS-treated (red) groups. (F) His-
tological assessment of the mean islet diam-
eter determined in formalin-fixed, paraffin-
embedded murine pancreas specimens (n = 3 
mice per group). Data represent the mean ± 
SEM (A–E) or the mean ± SD (F) of the indi-
cated number of mice. *P < 0.05, **P ≤ 0.01, 
and ***P ≤ 0.001, by 1-way ANOVA.
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greater RAGE/insulin overlap in human diabetic islets may reflect 
the fact that these human subjects had longstanding T2D, while 
the mice were not diabetic. Thus, the differences in staining pat-
terns may well be due to the presence of other glycemia-induced 
RAGE ligands in diabetic human islets. We confirmed the absence 
of RAGE ligands (S100B and AGEs) in our murine Tg/PBS islets 
(Supplemental Figures 9 and 10) and their presence in diabetic 
human islets compared with ND islets (data not shown). Together, 
the human data support our in vitro, ex vivo, and in vivo findings 
and indicate that pancreatic islet amyloidosis is associated with 
the upregulation of β cell RAGE expression in T2D.
Discussion
Our data provide the first evidence to our knowledge that RAGE 
selectively binds to a distinct, transient population of toxic prefi-
brillar h-IAPP intermediates and plays a role in h-IAPP–induced 
cellular perturbation in pancreatic islet amyloidosis (Figure 12). 
Several lines of evidence strongly support this conclusion. First, 
RAGE was upregulated in β cells prior to cellular metabolic dys-
function, coincident with the upregulation of inflammatory medi-
ators in vitro; in isolated murine islets after challenge with toxic 
h-IAPP intermediates, leading to loss of islet viability ex vivo; in 
as has been previously reported (10). No amyloid was detected 
in ND human islets. h-IAPP immunoreactivity in T2D islets 
colocalized with thioflavin-S+ and insulin– islet areas, as well as 
thioflavin-S– and insulin+ islet areas, suggesting that the antibody 
detects different forms of h-IAPP (Supplemental Figure 13). We 
found that islet amyloid deposition in human T2D was accom-
panied by a significant increase in islet β cell RAGE immunore-
activity compared with ND human islets (Figure 11 and Supple-
mental Table 2). Human T2D RAGE+ islet areas colocalized with 
insulin+ and h-IAPP+ islet areas.
The RAGE staining pattern in human islets appeared differ-
ent than that observed in murine islets. In both human and murine 
islets, we detected RAGE expression on the surface of cells. Close 
examination revealed that RAGE immunoreactivity in murine 
islets was more intense and punctate and located on insulin+, 
insulinlo, and insulin– islet areas, consistent with the ubiquitous 
expression of RAGE, and was increased on insulin+ cells in Tg/
PBS mice (Figure 10A). RAGE immunoreactivity in human islets 
colocalized predominantly with insulin+ cells in both diabetic 
and ND islets (Figure 11A). The ring-like pattern suggests that 
RAGE expression in human islets is more uniform and covers a 
larger area of the β cell surface than is seen in murine islets. The 
Figure 8. Pancreata of hemi_h-IAPP mice show 
upregulation of inflammatory genes, which 
is ameliorated by sRAGE treatment. qPCR 
analysis of whole pancreas samples from mice 
in PBS-treated (red bar) and sRAGE-treated 
(blue bar) groups. Data represent the mean ± 
SEM of 3 to 4 mice per group (n = 3–9 technical 
replicates per mouse) and are presented as the 
fold change relative to WT/PBS mice. *P < 0.05 
and **P ≤ 0.01, by 1-way ANOVA. Data in the 
ll18 graph were not normally distributed and are 
thus reported as the mean ± SD and were sta-
tistically analyzed by nonparametric methods 
(see Methods).
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dysfunction, and apoptosis. Third, sRAGE is an inhibitor of both 
h-IAPP toxicity and amyloid formation in vitro and in vivo. Fourth, 
RAGE binds only to toxic h-IAPP LP intermediates, while nontoxic 
forms of IAPP (r-IAPP, h-IAPP t0 species, and amyloid fibrils) do 
not bind RAGE. These observations, together with the findings of 
other studies that implicate a role for receptor-mediated mecha-
nisms of toxicity, are consistent with extracellular islet amyloid 
formation but do not exclude the possibility of additional intracel-
lular mechanisms of toxicity (6, 17, 33, 39).
a Tg mouse model of early islet amyloidosis with h-IAPP–induced 
glucose intolerance, loss of islet β cell area, and upregulation of 
inflammatory pancreatic mRNA transcripts in vivo; and in pan-
creatic islet β cells from human subjects with islet amyloido-
sis and T2D. Second, inhibiting RAGE activity by genetic Ager 
deletion, using blocking IgGs to prevent cellular h-IAPP/RAGE 
interactions, or sequestering h-IAPP intermediates with sRAGE 
to neutralize their toxicity protected cells and pancreatic islets 
from h-IAPP–induced inflammatory gene expression, metabolic 
Figure 9. Islet amyloid deposition, β cell stress, and apoptosis are suppressed by sRAGE treatment in hemi_h-IAPP mice. (A) Representative murine 
islets costained in pancreas for insulin (Ins, red) and thioflavin-S (Thio-S, green) show spatial overlap between insulin– (black) and thioflavin-S+ islet 
areas. Scale bars: 50 μm. Quantitative immunofluorescence image analysis of (B) islet amyloid severity and (C) islet β cell area. (D) Representative murine 
islets costained in pancreas show colocalization (yellow) of insulin (red) and CC3 (green) immunoreactive islet areas. Scale bars: 50 μm. (E) Quantitative 
immunofluorescence image analysis of CC3+ (stressed/preapoptotic) β cell area. (F) Representative murine islets costained in pancreas show colocaliza-
tion (magenta) of TUNEL+ (red) and DAPI+ (blue) cell nuclei in insulin+ (green) β cells. Scale bars: 50 μm and 8 μm (enlarged insets of β cell regions in white 
boxed areas in A, D, and F). (G) Quantitative immunofluorescence image analysis of TUNEL+ (apoptotic) β cell area. Data represent the mean ± SEM of 3 
mice per group. *P < 0.05, **P ≤ 0.01, ***P ≤ 0.001, and ****P ≤ 0.0001, by 1-way ANOVA.
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creas samples was diluted by mRNA extracts from other cell types 
besides β cells, our data still demonstrate a potent in vivo suppres-
sion of multiple inflammatory mediators by sRAGE. Interestingly, 
treatment of hemi_h-IAPP mice with sRAGE did not lead to lower 
Ccl2 gene expression, suggesting a possible role for infiltration 
and/or alternative polarization of monocytes and macrophages in 
Tg/sRAGE mice. Further studies are needed to determine the role 
of infiltrating immune cells in the pathophysiology of islet amyloi-
dosis and the pharmacology of sRAGE. Collectively, these results 
provide another connection between h-IAPP–induced toxicity 
and inflammation and suggest that amyloidogenic h-IAPP aug-
ments inflammation in pancreatic islet amyloidosis via receptor- 
mediated processes, such as recruitment of monocytes/mac-
rophages and other myeloid cells, and activation of the RAGE 
pathway in β cells. These considerations are in line with studies 
supporting the hypothesis that h-IAPP induces toxicity by multiple 
and complementary mechanisms (17, 39).
Extensive studies have indicated that adaptive IAPP has a 
physiological role in the regulation of glucose homeostasis via 
paracrine mechanisms in the pancreatic islets as well as autocrine 
mechanisms and effects on the central nervous system, and that 
modulation of IAPP production and/or secretion in pathological 
settings leads to alterations in glucose metabolism (6). A number 
of in vivo and in vitro experiments have demonstrated that IAPP 
has an inhibitory effect on insulin secretion (62, 63) and glucagon 
secretion (64, 65). Studies have shown that the decoupling of IAPP 
and insulin gene expression and secretion in pathological condi-
tions promotes IAPP overproduction and impaired glucose toler-
ance, but not insulin resistance (62, 66–68). The hemi_h-IAPP 
mouse model used in our studies oversecretes h-IAPP, a process 
The receptor-binding capabilities of IAPP hormones are well 
documented. The physiological roles of adaptive IAPP are medi-
ated by the IAPP receptor (55). Pathological receptor-mediated 
mechanisms have also been reported for h-IAPP (33). Our studies 
show that preamyloid h-IAPP intermediates are ligands of RAGE 
and define the mode of h-IAPP/RAGE interaction. While multiple 
overlapping mechanisms probably play a role in IAPP toxicity (17, 
39), this work demonstrates that RAGE-mediated processes clear-
ly contribute to and may be one of the pivotal initiating events 
for many of the downstream cellular pathways associated with 
h-IAPP toxicity. Our findings are consistent with the hypothesis 
that many amyloidogenic proteins invoke common mechanisms 
of cytotoxicity (56) and provide a foundation and blueprint for 
defining distinct, toxic RAGE-binding entities in other amyloido-
sis diseases for which RAGE has been postulated to impart patho-
genic consequences (57–61).
h-IAPP–induced β cell proteotoxicity is linked to local islet 
inflammatory processes (40, 42, 44, 45). Activation of inflamma-
somes by h-IAPP aggregates triggers the production of Il1b, sug-
gesting that Il1b enhances h-IAPP toxicity (40). Our in vitro and in 
vivo studies showing a RAGE-dependent increase in Il1b and Il18 
mRNA transcripts in β cells and in hemi_h-IAPP murine pancreas 
support these findings. We show that upregulation of the pro-
inflammatory mediators by h-IAPP was prevented by sRAGE. Our 
studies in hemi_h-IAPP mice demonstrating a significant increase 
in RAGE immunoreactivity on the surface of insulin+ β cells and a 
trend toward increased Ager gene expression in whole pancreas, 
in parallel with the same cytokines and chemokines, are consis-
tent with previous reports on h-IAPP–expressing Tg mouse mod-
els (44, 45). While the Ager gene expression signal in whole pan-
Figure 10. RAGE is upregulated in 
pancreatic islet amyloidosis. (A) Rep-
resentative islets in pancreas costained 
for insulin (red) and RAGE (green) 
show a significant increase in punctate 
RAGE+ areas localized on the surface of 
β cells in Tg/PBS mice compared with 
WT/PBS mice. Scale bars: 50 μm and 
8 μm (enlarged insets of β cell regions 
in white boxed areas). (B) Quantitative 
immunofluorescence image analysis of 
the percentage of RAGE+ islet area rela-
tive to the total insulin+ β cell area. Data 
represent the mean ± SEM of 3 mice per 
group. *P < 0.05, by 1-way ANOVA. (C) 
Linear regression analysis showing that 
the RAGE+ islet β cell area was associ-
ated with loss of β cell area in Tg/PBS 
mice with prediabetes and early-stage 
islet amyloidosis. P < 0.01; r2 = 0.215,  
by Wald test.
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size of Tg/PBS islets compared with WT control islets was statis-
tically significant (P ≤ 0.001). This may be due in part to age and 
in response to an increased demand for insulin to control impaired 
glucose tolerance resulting from hypersecretion of h-IAPP. The late 
onset of observed β cell defects suggests that the alteration in glu-
cose metabolism is a slow process in this model. In this case, the 
mice may have been able to compensate during the period before 
the onset of amyloidogenesis and the subsequent increase in apop-
tosis that was detected later at 12 months, which hindered the 
adaptive increase in β cell mass (54). Studies have shown that the 
total pancreatic β cell mass seen in rodents after birth is a balance 
between β cell replication from existing β cells, β cell production 
(differentiation) from other sources, and β cell apoptosis, and that 
the formation and maintenance of adult β cells depend largely on 
sources independent of β cell duplication (72), as the rate of β cell 
that is driven by the insulin II promoter, and recapitulates the 
h-IAPP hypersecretion observed in glucose intolerance. Previous 
studies have reported increased blood glucose levels in this Tg 
mouse model compared with levels in WT mice (53). We did not 
observe hyperglycemia in this model but did detect impaired glu-
cose tolerance in the mice at 12 months of age, along with pancreat-
ic inflammation, high levels of β cell stress and apoptosis, increased 
islet size, and a significant decrease in total islet β cell area in Tg/
PBS versus WT/PBS mice, consistent with β cell compensation 
in response to increased insulin requirements in mice (69, 70). 
While hyperplasia is not a typical characteristic of most h-IAPP 
Tg mouse strains, and the variation in islet sizes in the mice used 
in our studies made it difficult to conclusively diagnose hyperpla-
sia, as defined by the Department of Health and Human Services 
National Toxicology Program (71), the observed increase in the 
Figure 11. RAGE immunoreactivity in 
human T2D islets colocalizes with insulin+ 
and h-IAPP+ β cells. (A) Representative 
images of pancreatic islets from T2D (nPOD 
ID 6124) and ND (nPOD ID 6011) human 
subjects. Islets were triple stained for insulin 
(red), h-IAPP (blue), and RAGE (green) and 
show colocalization (yellow and cyan) of 
RAGE+ islet areas with insulin+ and h-IAPP+  
β cells. Scale bars: 50 μm and 8 μm (enlarged 
insets of β cell regions in white boxed areas). 
(B) Quantitative immunofluorescence image 
analysis shows a significant increase in the 
RAGE+ β cell area in T2D compared with ND 
islets. Data represent the mean ± SEM of 8 
T2D subjects and 7 ND subjects. **P < 0.01, 
by 2-tailed Student’s t test.
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processes; and preserved β cell area and overall β cell and islet 
morphology. We believe that the dual therapeutic action of sRAGE 
presents a new paradigm for antiamyloidosis agents. First, sRAGE 
sequesters and neutralizes h-IAPP intermediates, inhibiting their 
interaction with RAGE and other cell-surface binding sites, which 
in turn blocks consequent downstream events leading to toxicity. 
Second, sRAGE prevents the polymerization of toxic intermedi-
ates into amyloid fibrils. While fibrillar h-IAPP is not directly cyto-
toxic, the accumulation of amyloid plaque causes physical disrup-
tion in tissue architecture, elasticity, and homeostasis and thus 
may contribute to cumulative cellular perturbations.
Our studies define the mode of interaction between toxic 
h-IAPP species and cellular RAGE. Many RAGE ligands are anionic 
and are thought to bind to the basic patch on the receptor surface. 
h-IAPP is cationic and hydrophobic and would thus be expected 
to repel the basic patch. The data presented here, which indicate 
a close proximity of h-IAPP with the solvent-exposed sRAGE Trp 
residues, suggest that toxic h-IAPP intermediates probably bind to 
the hydrophobic patch on RAGE, highlighting this receptor region 
as an important site for the engagement of pathogenic species and 
a potential drug target. This is an important consideration for the 
design of inhibitors of RAGE activation in pancreatic islet amyloi-
dosis, as the inhibitors of the extracellular RAGE domains that tar-
get the basic patch may be ineffective at blocking interactions with 
distinct hydrophobic ligands, such as h-IAPP.
In summary, we have identified a RAGE-mediated cellular 
mechanism of h-IAPP–induced β cell toxicity in pancreatic islet 
amyloidosis that precedes the development of hyperglycemia. 
Further, this work has unveiled an unanticipated dual therapeutic 
advantage of sRAGE as an inhibitor of both h-IAPP toxicity and 
amyloid formation itself. We believe these findings fill a critical 
gap in knowledge and advance our understanding in the field of 
IAPP biology, as well as across the field of amyloidosis diseases by 
identifying a new mediator of proteotoxicity that has significant 
therapeutic implications for β cell preservation and mitigation of 
consequent metabolic dysfunction.
replication in rodents declines with age (73). Our in vivo studies 
were not longitudinal and can only provide a snapshot at the time 
of sacrifice. Thus, we are limited in our ability to speculate about 
the rates of β cell proliferation, differentiation, or apoptosis other 
than to say that the rates of β cell compensation and apoptosis were 
probably not linear; rather, they progressively accelerated at differ-
ent rates and different time points over the 12-month period, with 
advancing glucose intolerance and islet amyloidosis.
Our in vivo studies confirm the physiological relevance of our in 
vitro and ex vivo findings and are in line with previous reports that 
this hemi_h-IAPP mouse model develops β cell degeneration and 
early-stage pancreatic islet amyloidosis in the absence of diabetes 
(53). This 12-month-old mouse model decouples islet amyloidosis–
induced metabolic dysfunction from the additive effects of hyper-
glycemia and indicates that the onset of islet amyloidosis occurs 
before the onset of diabetes and is not a consequence of the disease. 
The data presented in Figure 9, Figure 10, and Supplemental Figure 
12, which together demonstrate a direct relationship between the 
loss of β cell area and β cell stress, apoptosis, and RAGE expression 
in Tg/PBS mice, and a lack of correlation between these parameters 
and islet amyloid area, are all normally distributed and statistically 
significant. The lack of correlation between islet amyloid severity 
and the extent of β cell stress, apoptosis, and loss of β cell area is in 
line with previous reports (54) and supports our other in vitro and 
in vivo findings that toxic preamyloid h-IAPP intermediates, which 
gradually form and build up during the slow LP of amyloid forma-
tion, are more deleterious than the final thioflavin+ amyloid fibrils. 
Our in vivo findings also establish a role for RAGE in islet amyloi-
dosis–induced β cell proteotoxicity. Our human pancreas studies 
show an association between increased β cell RAGE expression and 
h-IAPP amyloidosis in human T2D. Together, our in vivo findings 
highlight the interaction of RAGE and h-IAPP intermediates as a 
primary target for β cell and islet preservation in metabolic disease.
The administration of sRAGE in vitro and in a murine model 
of pancreatic islet amyloidosis blocked toxicity, proinflammatory 
mediators, and amyloid formation; promoted anti-inflammatory 
Figure 12. Schematic diagram illustrating a 
RAGE-mediated mechanism of h-IAPP cyto-
toxicity and the 2-prong therapeutic advantage 
of sRAGE. sRAGE has dual beneficial roles as a 
therapeutic agent for islet amyloidosis, as it (a) 
binds specifically to the toxic preamyloid form of 
h-IAPP that induce cellular stress, inflammation, 
metabolic dysfunction and apoptosis; and (b) 
prevents further assembly of the toxic interme-
diates into amyloid fibrils that accumulate into 
plaques and disrupt cell and tissue homeostasis. 
Binding of sRAGE to toxic h-IAPP intermediates 
also averts binding of the intermediates to other 
cell-surface binding sites besides RAGE, thus 
significantly blocking cytotoxicity and associated 
pathological consequences.
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from peptide stock solutions or controls. Hand-purified islets of the 
same size and number (25 islets/well in 96-well plates) were incu-
bated for 3 to 5 hours with peptide solutions or controls. Final peptide 
concentrations in cellular and islet assays were 14 μM. Cell and islet 
viability was assessed by Alamar Blue metabolic assays (76) and light 
microscopy, as previously described (19). Values were calculated rela-
tive to those of control cells or islets treated with buffer or r-IAPP. Data 
from islet experiments were normalized to the total number of islets 
per well. β Cell viability data represent numerous (>20) experiments 
carried out at different times by different laboratory members using 
multiple preparations of peptide stock solutions.
Light microscopy. Changes in cell and islet morphology were exam-
ined by light microscopy as an additional method of evaluating viabil-
ity. Images were captured using an Olympus BX-61 light microscope.
RAGE blockade assays. Blocking antibodies were produced at the 
Pocono Rabbit Farm & Laboratory, Inc. using previously described 
methods (77). INS-1 β cells were plated at a density of 30,000 cells per 
well in 96-well plates 24 hours before experiments. Cells were pretreat-
ed (2.5 hours) with either rabbit anti–human RAGE IgG or rabbit nonim-
mune IgG prior to challenge (5 hours) with toxic h-IAPP intermediates 
(14 μM). Cell viability was measured by Alamar Blue metabolic assays.
RNA isolation and qPCR. Total cellular RNA and tissue RNA were 
isolated from β cells, SMCs, or pancreas specimens using the RNeasy 
Plus Mini Kit or RNeasy Fibrous Tissue Mini Kit (QIAGEN). The qual-
ity of RNA was determined by measurement of a 260:280 ratio. RNA 
(1 μg) was reverse transcribed to cDNA with MultiScribe Reverse 
Transcriptase (Applied Biosystems). Real-time qPCR was performed 
using the TaqMan method (50°C for 2 min, 95°C for 10 min, and 40 
cycles of 95°C for 15 seconds and 60°C for 1 min) with premade Ager, 
Ccl2, Cxcl1, Cxcl2, Il1b, Il18, Il10, Tnfa, and Vcam1 primers (Life Tech-
nologies, Thermo Fisher Scientific). Relative mRNA contents were 
normalized according to the expression of 18S rRNA using the ΔΔCt 
method. qPCR was performed using an Applied Biosystems 7500 
Real-time PCR machine.
WB analysis. Proteins (25–60 μg per lane) isolated from β cells or 
murine pancreatic islets were separated on a 4%–12% Bis-Tris NuPAGE 
gel (Bio-Rad) and transferred onto a PVDF membrane. Membranes 
were probed overnight (4°C) with the following primary antibodies: 
rabbit anti-RAGE (1:1,000; GeneTex; GTX23611) and anti–mouse 
GAPDH (1:1,000; Abcam; ab8245), followed by the following sec-
ondary antibodies (1 hour, 25°C): IRDye 800EW goat anti–rabbit IgG 
(1:10,000; LI-COR; 925-32211) for detection of RAGE, and IRDye 
680RD goat anti–mouse IgG (1:25,000; LI-COR; 925-68070) for 
detection of GAPDH. Protein signals were quantified using the Odys-
sey Infrared Imaging System (LI-COR; model 9120). RAGE protein 
signals were normalized to GAPDH protein signals in the same lane.
TEM. Samples (4 μl) were placed on a carbon-coated, 200-mesh 
copper grid and negatively stained with saturated uranyl acetate (Elec-
tron Microscopy Sciences). The samples were imaged with a Philips 
CM12 or a FEI BioTwinG2 transmission electron microscope.
Thioflavin-T binding assays. Aliquots (100 μl) of peptide solutions 
were added to 96-well plates containing 8 μl of a 1 mM thioflavin-T 
solution (Sigma-Aldrich). The final solution conditions contained 15 
or 25 μM peptide, 20 mM Tris HCl, and 74 μM thioflavin-T (pH 7.4). 
Fluorescence was measured using a Beckman Coulter DTX880 plate 
reader (excitation, 445 nm; emission, 485 nm). Additional informa-
tion can be found in the Supplemental Methods.
Methods
Human pancreas studies. Sections of paraffin-embedded or frozen 
OCT-embedded pancreas specimens previously prepared from dei-
dentified T2D (n = 8) and ND (n = 7) human subjects were obtained 
from nPOD. Tissue IHC-immunofluorescence (IHC-IF) methods 
were optimized directly in the control human pancreatic tissue. Clini-
cal and immunohistological data for each subject can be found in Sup-
plemental Table 2.
Mouse studies. Hemizygous Tg mice that overexpress the amy-
loidogenic h-IAPP–coding sequence under the regulation of the 
rat insulin II promoter 5′-UTR (The Jackson Laboratory) have been 
described previously (26, 53). Male mice were fed a normal chow diet 
and treated with 100 μl i.p. injections of either sRAGE (100 μg/ml) 
or PBS 6 days a week for 10 months to produce 4 age-matched study 
groups: Tg/PBS, Tg/sRAGE, WT/PBS, and WT/sRAGE. Body weight, 
fasting blood glucose, and i.p. glucose tolerance tests (ip-GTTs) were 
measured over the course of the study, and fasting plasma insulin 
measurements and analysis of islet size, morphology, and pathology 
by histological methods were carried out after sacrifice, as described 
in the Supplemental Methods.
IHC-IF. Six sections of formalin-fixed, paraffin-embedded pancre-
as specimens (4 μm thick and 30–200 μm apart) were labeled for each 
marker. All murine and human pancreas sections were stained with pri-
mary and secondary antibodies for detection of insulin, amyloid, CC3, 
TUNEL, RAGE, AGEs, S100B, and IAPP. Images were taken using a 
Leica fluorescence microscope. Quantitative analysis using MetaMorph 
LASF imaging software was performed by an investigator blinded to the 
experimental condition. Detailed methods for histological studies can 
be found in Supplemental Table 1 and the Supplemental Methods.
Cell culture. The rat insulinoma cell line 832/13 (INS-1 β cells) was 
provided by Christopher Newgard (Duke University School of Medi-
cine, Durham, North Carolina, USA) (74). Murine vascular SMCs were 
obtained from the aortas of 10-week-old male C57BL/6 mice (The 
Jackson Laboratory) or Ager–/– mice (52). Detailed cell culture methods 
can be found in the Supplemental Methods.
Islet isolation and culture. Pancreatic islets were isolated from anes-
thetized 12- to 18-week-old C57BL/6 mice (The Jackson Laboratory) or 
Ager–/– mice (52) according to institutional guidelines, hand purified, 
and cultured in supplemented RPMI 1640 medium, as described in 
the Supplemental Methods.
Protein preparation. IAPP peptides were prepared as previously 
described (19) or purchased from the KECK Foundation at Yale 
University (New Haven, Connecticut, USA). Human sRAGE was 
prepared via a baculovirus expression system using Sf9 cells (Clon-
tech, Invitrogen, Thermo Fisher Scientific) (75), as described in the 
Supplemental Methods.
Amyloid formation assays. Amyloid formation reactions were ini-
tiated as previously described (19) and were monitored using thio-
flavin-T binding assays. Aliquots were removed from stock solutions at 
various time points over the course of amyloid formation and further 
characterized by difference-CD and TEM.
Toxicity assays. INS-1 β cells were seeded at a density of 30,000 
cells per well in 96-well plates 24 hours prior to experiments and incu-
bated for 1 or 5 hours with aliquots of peptide solutions or controls. 
SMCs were seeded at a density of 300,000 cells per well in 6-well 
plates 36 hours before experiments, switched to serum-free DMEM 12 
hours before experiments, and incubated for 10 hours with aliquots 
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to work with Organ Procurement Organizations (OPOs) to obtain tis-
sue from organ donors in the U.S. Adults who have registered while 
alive to become an organ donor upon their passing are considered to 
have granted consent for organ recovery for transplant and research. 
If the donor is a minor child, or is an adult who has not independently 
registered, the OPO approaches the legal next-of-kin for consent. The 
58 OPOs in the U.S. operate regionally, and each have a version of a 
patient consent form. OPOs within the U.S. are members of the Organ 
Procurement and Transplantation Network (OPTN) and are overseen 
by the United Network for Organ Sharing (UNOS).
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Far UV CD. Far UV CD was performed using an Applied Photo-
physics spectrophotometer. Aliquots (300 μl) were transferred from 
amyloid formation assays to a 0.1 cm quartz cuvette within a few min-
utes prior to data collection. Spectra were recorded over a range of 
190 to 260 nm, and CD spectra represented the average of 5 repeats. 
Background spectra were subtracted. In difference-CD experiments, 
the spectra for solutions of sRAGE alone, which were collected at the 
same time as respective h-IAPP/sRAGE mixtures, were subtracted 
from the spectra of h-IAPP/sRAGE mixtures. The samples contained 
20 mM tris HCl (pH 7.4).
Trp fluorescence and SPR. sRAGE Trp fluorescence (280 nm excita-
tion; 350 nm emission) was measured using a Photon Technology Inter-
national instrument. The signal was an average of 20 reads over 20 sec-
onds (2.5 nm bandwidth and 1-second integration time). In SPR studies, 
sRAGE was immobilized on the sensor chip, and the interaction of dif-
ferent h-IAPP species with sRAGE was measured using a GE Healthcare 
SPR instrument. The final peptide concentrations were 20 μM h-IAPP 
or r-IAPP and 20 μM sRAGE in 20 mM Tris-HCl (pH 7.4, 25°C).
Statistics. Data analysis was carried out in collaboration with 
biostatisticians using appropriate statistical analysis methods deter-
mined by the distribution type and sample size of the data sets. Nor-
mally distributed data, as judged by the Shapiro-Wilk normality test, 
are presented as either mean ± SEM or mean ± SD of n independent 
experiments (as reported in each figure legend), as appropriate. Data 
that did not pass the Shapiro-Wilk normality test [Figure 8 (Il18 panel 
only) and Supplemental Figure 4] are presented as mean ± SD. For 
multiple-group comparisons, normally distributed data were ana-
lyzed by one-way or two-way ANOVA, as appropriate, followed by 
post hoc Tukey HSD for pairwise comparisons, or post hoc paired 
t-test for a pre-selected set of group comparisons. For two-group com-
parisons, normally distributed data were first analyzed by the F-test 
to compare variances between two groups, followed by two sample 
2-tailed t-test with equal or unequal variance. Data that did not pass 
the Shapiro-Wilk normality test were assessed by the Kruskal-Wallis 
rank sum test followed by Dunn’s post hoc group comparison test. 
Data were corrected for multiple comparisons using the Benjamini– 
Hochberg multiple comparison correction; an adjusted P value of 
<0.05 was considered significant. The significance of the linear 
regression analyses in correlation studies was determined by the 
Wald test; a P value of <0.05 was considered significant. For paired 
group comparisons, ANOVA with post hoc test results of P < 0.1 but 
> 0.05 were considered non-significant trends.
Study approval. All animal procedures were approved by the 
IACUC of New York University and performed in accordance with 
NIH animal care guidelines. All deidentified human studies were IRB 
exempt, as determined by the NYU School of Medicine IRB. nPOD is a 
research organization based in Gainesville, FL, that operates under the 
approval of the University of Florida’s IRB. This approval allows nPOD 
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